Kyunghee Burkitt, Do, Phd

This early-stage study is testing whether adding an experimental drug called decitabine can make an approved immunotherapy (nivolumab) work better against recurrent or spreading head and neck cancer. The main goals are to find the safest dose of the combination and see how it aff…